The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global GIP-1 Receptor Agonist Market Research Report 2024
Synopsis
GIP-1 receptor agonists are a class of drugs for the treatment of type 2 diabetes. This type of drug can exert the effect of incretin by stimulating the glucagon-like peptide-1 receptor to produce a hypoglycemic effect. showed advantages in protection.
Global GIP-1 Receptor Agonist market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GIP-1 Receptor Agonist market research.
Key manufacturers engaged in the GIP-1 Receptor Agonist industry include GSK, Novo Nordisk, Eli Lilly and Company, Baxter Pharmaceutical Solutions, Sanofi, AstraZeneca, Shanghai Benemae Pharmaceutical Corporation, Sinopep Allsino Bio Pharmaceutical and Huadong Medicine, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GIP-1 Receptor Agonist were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GIP-1 Receptor Agonist market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global GIP-1 Receptor Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
Novo Nordisk
Eli Lilly and Company
Baxter Pharmaceutical Solutions
Sanofi
AstraZeneca
Shanghai Benemae Pharmaceutical Corporation
Sinopep Allsino Bio Pharmaceutical
Huadong Medicine
HANSOH PHARMA
3SBio
Segment by Type
Short-acting GLP-1 Receptor Agonist
Long-acting GLP-1 Receptor Agonist
Segment by Application
Type 2 Diabetics
Obese Patients
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GIP-1 Receptor Agonist report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
GIP-1 receptor agonists are a class of drugs for the treatment of type 2 diabetes. This type of drug can exert the effect of incretin by stimulating the glucagon-like peptide-1 receptor to produce a hypoglycemic effect. showed advantages in protection.
Global GIP-1 Receptor Agonist market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GIP-1 Receptor Agonist market research.
Key manufacturers engaged in the GIP-1 Receptor Agonist industry include GSK, Novo Nordisk, Eli Lilly and Company, Baxter Pharmaceutical Solutions, Sanofi, AstraZeneca, Shanghai Benemae Pharmaceutical Corporation, Sinopep Allsino Bio Pharmaceutical and Huadong Medicine, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GIP-1 Receptor Agonist were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GIP-1 Receptor Agonist market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global GIP-1 Receptor Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
Novo Nordisk
Eli Lilly and Company
Baxter Pharmaceutical Solutions
Sanofi
AstraZeneca
Shanghai Benemae Pharmaceutical Corporation
Sinopep Allsino Bio Pharmaceutical
Huadong Medicine
HANSOH PHARMA
3SBio
Segment by Type
Short-acting GLP-1 Receptor Agonist
Long-acting GLP-1 Receptor Agonist
Segment by Application
Type 2 Diabetics
Obese Patients
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GIP-1 Receptor Agonist report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 GIP-1 Receptor Agonist Market Overview
1.1 Product Overview and Scope of GIP-1 Receptor Agonist
1.2 GIP-1 Receptor Agonist Segment by Type
1.2.1 Global GIP-1 Receptor Agonist Market Value Comparison by Type (2023-2029)
1.2.2 Short-acting GLP-1 Receptor Agonist
1.2.3 Long-acting GLP-1 Receptor Agonist
1.3 GIP-1 Receptor Agonist Segment by Application
1.3.1 Global GIP-1 Receptor Agonist Market Value by Application: (2023-2029)
1.3.2 Type 2 Diabetics
1.3.3 Obese Patients
1.3.4 Others
1.4 Global GIP-1 Receptor Agonist Market Size Estimates and Forecasts
1.4.1 Global GIP-1 Receptor Agonist Revenue 2018-2029
1.4.2 Global GIP-1 Receptor Agonist Sales 2018-2029
1.4.3 Global GIP-1 Receptor Agonist Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 GIP-1 Receptor Agonist Market Competition by Manufacturers
2.1 Global GIP-1 Receptor Agonist Sales Market Share by Manufacturers (2018-2023)
2.2 Global GIP-1 Receptor Agonist Revenue Market Share by Manufacturers (2018-2023)
2.3 Global GIP-1 Receptor Agonist Average Price by Manufacturers (2018-2023)
2.4 Global GIP-1 Receptor Agonist Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of GIP-1 Receptor Agonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GIP-1 Receptor Agonist, Product Type & Application
2.7 GIP-1 Receptor Agonist Market Competitive Situation and Trends
2.7.1 GIP-1 Receptor Agonist Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest GIP-1 Receptor Agonist Players Market Share by Revenue
2.7.3 Global GIP-1 Receptor Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 GIP-1 Receptor Agonist Retrospective Market Scenario by Region
3.1 Global GIP-1 Receptor Agonist Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global GIP-1 Receptor Agonist Global GIP-1 Receptor Agonist Sales by Region: 2018-2029
3.2.1 Global GIP-1 Receptor Agonist Sales by Region: 2018-2023
3.2.2 Global GIP-1 Receptor Agonist Sales by Region: 2024-2029
3.3 Global GIP-1 Receptor Agonist Global GIP-1 Receptor Agonist Revenue by Region: 2018-2029
3.3.1 Global GIP-1 Receptor Agonist Revenue by Region: 2018-2023
3.3.2 Global GIP-1 Receptor Agonist Revenue by Region: 2024-2029
3.4 North America GIP-1 Receptor Agonist Market Facts & Figures by Country
3.4.1 North America GIP-1 Receptor Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America GIP-1 Receptor Agonist Sales by Country (2018-2029)
3.4.3 North America GIP-1 Receptor Agonist Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe GIP-1 Receptor Agonist Market Facts & Figures by Country
3.5.1 Europe GIP-1 Receptor Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe GIP-1 Receptor Agonist Sales by Country (2018-2029)
3.5.3 Europe GIP-1 Receptor Agonist Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GIP-1 Receptor Agonist Market Facts & Figures by Country
3.6.1 Asia Pacific GIP-1 Receptor Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific GIP-1 Receptor Agonist Sales by Country (2018-2029)
3.6.3 Asia Pacific GIP-1 Receptor Agonist Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GIP-1 Receptor Agonist Market Facts & Figures by Country
3.7.1 Latin America GIP-1 Receptor Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America GIP-1 Receptor Agonist Sales by Country (2018-2029)
3.7.3 Latin America GIP-1 Receptor Agonist Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa GIP-1 Receptor Agonist Market Facts & Figures by Country
3.8.1 Middle East and Africa GIP-1 Receptor Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa GIP-1 Receptor Agonist Sales by Country (2018-2029)
3.8.3 Middle East and Africa GIP-1 Receptor Agonist Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GIP-1 Receptor Agonist Sales by Type (2018-2029)
4.1.1 Global GIP-1 Receptor Agonist Sales by Type (2018-2023)
4.1.2 Global GIP-1 Receptor Agonist Sales by Type (2024-2029)
4.1.3 Global GIP-1 Receptor Agonist Sales Market Share by Type (2018-2029)
4.2 Global GIP-1 Receptor Agonist Revenue by Type (2018-2029)
4.2.1 Global GIP-1 Receptor Agonist Revenue by Type (2018-2023)
4.2.2 Global GIP-1 Receptor Agonist Revenue by Type (2024-2029)
4.2.3 Global GIP-1 Receptor Agonist Revenue Market Share by Type (2018-2029)
4.3 Global GIP-1 Receptor Agonist Price by Type (2018-2029)
5 Segment by Application
5.1 Global GIP-1 Receptor Agonist Sales by Application (2018-2029)
5.1.1 Global GIP-1 Receptor Agonist Sales by Application (2018-2023)
5.1.2 Global GIP-1 Receptor Agonist Sales by Application (2024-2029)
5.1.3 Global GIP-1 Receptor Agonist Sales Market Share by Application (2018-2029)
5.2 Global GIP-1 Receptor Agonist Revenue by Application (2018-2029)
5.2.1 Global GIP-1 Receptor Agonist Revenue by Application (2018-2023)
5.2.2 Global GIP-1 Receptor Agonist Revenue by Application (2024-2029)
5.2.3 Global GIP-1 Receptor Agonist Revenue Market Share by Application (2018-2029)
5.3 Global GIP-1 Receptor Agonist Price by Application (2018-2029)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.1.4 GSK GIP-1 Receptor Agonist Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Novo Nordisk
6.2.1 Novo Nordisk Corporation Information
6.2.2 Novo Nordisk Description and Business Overview
6.2.3 Novo Nordisk GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novo Nordisk GIP-1 Receptor Agonist Product Portfolio
6.2.5 Novo Nordisk Recent Developments/Updates
6.3 Eli Lilly and Company
6.3.1 Eli Lilly and Company Corporation Information
6.3.2 Eli Lilly and Company Description and Business Overview
6.3.3 Eli Lilly and Company GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly and Company GIP-1 Receptor Agonist Product Portfolio
6.3.5 Eli Lilly and Company Recent Developments/Updates
6.4 Baxter Pharmaceutical Solutions
6.4.1 Baxter Pharmaceutical Solutions Corporation Information
6.4.2 Baxter Pharmaceutical Solutions Description and Business Overview
6.4.3 Baxter Pharmaceutical Solutions GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Baxter Pharmaceutical Solutions GIP-1 Receptor Agonist Product Portfolio
6.4.5 Baxter Pharmaceutical Solutions Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sanofi GIP-1 Receptor Agonist Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.6.4 AstraZeneca GIP-1 Receptor Agonist Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Shanghai Benemae Pharmaceutical Corporation
6.6.1 Shanghai Benemae Pharmaceutical Corporation Corporation Information
6.6.2 Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
6.6.3 Shanghai Benemae Pharmaceutical Corporation GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai Benemae Pharmaceutical Corporation GIP-1 Receptor Agonist Product Portfolio
6.7.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
6.8 Sinopep Allsino Bio Pharmaceutical
6.8.1 Sinopep Allsino Bio Pharmaceutical Corporation Information
6.8.2 Sinopep Allsino Bio Pharmaceutical Description and Business Overview
6.8.3 Sinopep Allsino Bio Pharmaceutical GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Sinopep Allsino Bio Pharmaceutical GIP-1 Receptor Agonist Product Portfolio
6.8.5 Sinopep Allsino Bio Pharmaceutical Recent Developments/Updates
6.9 Huadong Medicine
6.9.1 Huadong Medicine Corporation Information
6.9.2 Huadong Medicine Description and Business Overview
6.9.3 Huadong Medicine GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Huadong Medicine GIP-1 Receptor Agonist Product Portfolio
6.9.5 Huadong Medicine Recent Developments/Updates
6.10 HANSOH PHARMA
6.10.1 HANSOH PHARMA Corporation Information
6.10.2 HANSOH PHARMA Description and Business Overview
6.10.3 HANSOH PHARMA GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.10.4 HANSOH PHARMA GIP-1 Receptor Agonist Product Portfolio
6.10.5 HANSOH PHARMA Recent Developments/Updates
6.11 3SBio
6.11.1 3SBio Corporation Information
6.11.2 3SBio GIP-1 Receptor Agonist Description and Business Overview
6.11.3 3SBio GIP-1 Receptor Agonist Sales, Revenue and Gross Margin (2018-2023)
6.11.4 3SBio GIP-1 Receptor Agonist Product Portfolio
6.11.5 3SBio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GIP-1 Receptor Agonist Industry Chain Analysis
7.2 GIP-1 Receptor Agonist Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GIP-1 Receptor Agonist Production Mode & Process
7.4 GIP-1 Receptor Agonist Sales and Marketing
7.4.1 GIP-1 Receptor Agonist Sales Channels
7.4.2 GIP-1 Receptor Agonist Distributors
7.5 GIP-1 Receptor Agonist Customers
8 GIP-1 Receptor Agonist Market Dynamics
8.1 GIP-1 Receptor Agonist Industry Trends
8.2 GIP-1 Receptor Agonist Market Drivers
8.3 GIP-1 Receptor Agonist Market Challenges
8.4 GIP-1 Receptor Agonist Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
